Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Ramucirumab: first global approval.

Literature DB >> 24916147

Ramucirumab: first global approval.

Raewyn M Poole¹, Asha Vaidya.
1. Adis, Auckland, New Zealand.

Abstract

Ramucirumab (Cyramza™ [US]), a fully human immunoglobulin G1 (IgG1) monoclonal antibody that inhibits vascular endothelial growth factor receptor-2 (VEGFR-2), has been developed by Eli Lilly (formerly ImClone Systems) for the treatment of cancer. Ramucirumab has received its first global approval in the US for use as monotherapy in the treatment of advanced or metastatic gastric cancer or gastro-oesophageal junction adenocarcinoma in patients who experience disease progression on or after fluoropyrimidine- or platinum-containing chemotherapy. Ramucirumab is the first treatment to be approved by the US FDA for this setting. This article summarizes the milestones in the development of ramucirumab leading to this first approval for the treatment of gastric cancer and gastro-oesophageal junction adenocarcinoma.

Entities: Chemical Disease Gene Species

Mesh：

Substances：

Year: 2014 PMID： 24916147 DOI： 10.1007/s40265-014-0244-2

Source DB: PubMed Journal: Drugs ISSN： 0012-6667 Impact factor: 9.546

16 in total

Review 1. Targeted systemic therapies for hepatocellular carcinoma: clinical perspectives, challenges and implications.

Authors: Catherine Frenette; Robert Gish
Journal: World J Gastroenterol Date: 2012-02-14 Impact factor: 5.742

Review 2. Targeted inhibition of VEGF receptor 2: an update on ramucirumab.

Authors: Jeffrey Melson Clarke; Herbert I Hurwitz
Journal: Expert Opin Biol Ther Date: 2013-06-26 Impact factor: 4.388

3. Primary results of ROSE/TRIO-12, a randomized placebo-controlled phase III trial evaluating the addition of ramucirumab to first-line docetaxel chemotherapy in metastatic breast cancer.

Authors: John R Mackey; Manuel Ramos-Vazquez; Oleg Lipatov; Nicole McCarthy; Dmitriy Krasnozhon; Vladimir Semiglazov; Alexey Manikhas; Karen A Gelmon; Gottfried E Konecny; Marc Webster; Roberto Hegg; Sunil Verma; Vera Gorbunova; Dany Abi Gerges; Francois Thireau; Helena Fung; Lorinda Simms; Marc Buyse; Ayman Ibrahim; Miguel Martin
Journal: J Clin Oncol Date: 2014-09-02 Impact factor: 44.544

4. An open-label phase II study evaluating the safety and efficacy of ramucirumab combined with mFOLFOX-6 as first-line therapy for metastatic colorectal cancer.

Authors: Rocio Garcia-Carbonero; Fernando Rivera; Joan Maurel; Jean-Pierre M Ayoub; Malcolm J Moore; Andres Cervantes; Timothy R Asmis; Jonathan D Schwartz; Federico Nasroulah; Shaila Ballal; Josep Tabernero
Journal: Oncologist Date: 2014-03-27

5. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial.

Authors: Charles S Fuchs; Jiri Tomasek; Cho Jae Yong; Filip Dumitru; Rodolfo Passalacqua; Chanchal Goswami; Howard Safran; Lucas Vieira Dos Santos; Giuseppe Aprile; David R Ferry; Bohuslav Melichar; Mustapha Tehfe; Eldar Topuzov; John Raymond Zalcberg; Ian Chau; William Campbell; Choondal Sivanandan; Joanna Pikiel; Minori Koshiji; Yanzhi Hsu; Astra M Liepa; Ling Gao; Jonathan D Schwartz; Josep Tabernero
Journal: Lancet Date: 2013-10-03 Impact factor: 79.321

6. Prognostic value of vascular endothelial growth factor expression in gastric carcinoma.

Authors: K Maeda; Y S Chung; Y Ogawa; S Takatsuka; S M Kang; M Ogawa; T Sawada; M Sowa
Journal: Cancer Date: 1996-03-01 Impact factor: 6.860

7. Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2.

Authors: Jennifer L Spratlin; Roger B Cohen; Matthew Eadens; Lia Gore; D Ross Camidge; Sami Diab; Stephen Leong; Cindy O'Bryant; Laura Q M Chow; Natalie J Serkova; Neal J Meropol; Nancy L Lewis; E Gabriela Chiorean; Floyd Fox; Hagop Youssoufian; Eric K Rowinsky; S Gail Eckhardt
Journal: J Clin Oncol Date: 2010-01-04 Impact factor: 44.544

8. Metastatic gastric cancer - focus on targeted therapies.

Authors: Judith Meza-Junco; Michael B Sawyer
Journal: Biologics Date: 2012-06-20

9. The progress of targeted therapy in advanced gastric cancer.

Authors: Miao-Zhen Qiu; Rui-Hua Xu
Journal: Biomark Res Date: 2013-12-11

Review 10. VEGFA and tumour angiogenesis.

Authors: L Claesson-Welsh; M Welsh
Journal: J Intern Med Date: 2013-02 Impact factor: 8.989

23 in total

1. Anti-VEGFR2-interferon-α2 regulates the tumor microenvironment and exhibits potent antitumor efficacy against colorectal cancer.

Authors: Zhaoting Li; Yijia Zhu; Chenchen Li; Ryan Trinh; Xueyan Ren; Fumou Sun; Youfu Wang; Pengzhao Shang; Tong Wang; Min Wang; Sherie L Morrison; Juan Zhang
Journal: Oncoimmunology Date: 2017-02-17 Impact factor: 8.110

2. Incidence and risk of hypertension with ramucirumab in cancer patients: a meta-analysis of published studies.

Authors: Jianhua Wang; Zexing Wang; Yunzhao Zhao
Journal: Clin Drug Investig Date: 2015-04 Impact factor: 2.859

Review 3. Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021.

Authors: Qing Wu; Wei Qian; Xiaoli Sun; Shaojie Jiang
Journal: J Hematol Oncol Date: 2022-10-08 Impact factor: 23.168

4. DW10075, a novel selective and small-molecule inhibitor of VEGFR, exhibits antitumor activities both in vitro and in vivo.

Authors: Meng-yuan Li; Yong-cong Lv; Lin-jiang Tong; Ting Peng; Rong Qu; Tao Zhang; Yi-ming Sun; Yi Chen; Li-xin Wei; Mei-yu Geng; Wen-hu Duan; Hua Xie; Jian Ding
Journal: Acta Pharmacol Sin Date: 2016-01-25 Impact factor: 6.150

Review 10. Current Molecular Targeted Therapy in Advanced Gastric Cancer: A Comprehensive Review of Therapeutic Mechanism, Clinical Trials, and Practical Application.

Authors: Kaichun Li; Jin Li
Journal: Gastroenterol Res Pract Date: 2016-01-10 Impact factor: 2.260